231 related articles for article (PubMed ID: 19026169)
1. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women.
Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW
Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169
[TBL] [Abstract][Full Text] [Related]
2. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
4. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
5. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
6. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women.
Botella S; Restituto P; Monreal I; Colina I; Calleja A; Varo N
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1740-8. PubMed ID: 24001743
[TBL] [Abstract][Full Text] [Related]
7. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b.
Ohashi T; Igarashi Y; Mochizuki Y; Miura T; Inaba N; Katayama K; Tomonaga T; Nomura F
Clin Chim Acta; 2007 Feb; 376(1-2):205-12. PubMed ID: 17045980
[TBL] [Abstract][Full Text] [Related]
9. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
10. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
[TBL] [Abstract][Full Text] [Related]
11. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
12. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
[TBL] [Abstract][Full Text] [Related]
16. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
17. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
Uchida K; Nakanishi M; Yoh K
Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
[TBL] [Abstract][Full Text] [Related]
18. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
19. Age-related changes of serum bone alkaline phosphatase and cross-linked C-telopeptides of type I collagen and the relationship with bone mineral density in Chinese women.
Shan PF; Wu XP; Zhang H; Luo XH; Cao XZ; Xie H; Liu SP; Pi YZ; Fang TY; Liu H; Chen ZH; Zhong N; Liao EY
Clin Chim Acta; 2006 Apr; 366(1-2):233-8. PubMed ID: 16330011
[TBL] [Abstract][Full Text] [Related]
20. Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Postmenopausal Osteoporosis.
Wu Q; Zhong ZM; Pan Y; Zeng JH; Zheng S; Zhu SY; Chen JT
Med Sci Monit; 2015 Aug; 21():2428-32. PubMed ID: 26286507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
